

Journal Pre-proof

Eye Drop Instillation Success and Hand Function in Adults with Glaucoma: A Pilot Study

Madeline K. Weber, BS, Gül G. Kabil, BS, Leslie M. Niziol, MS, Daniel Duque Urrego, BSE, Cameron Haire, BSE, Stephen M. Cain, PhD, Alanson P. Sample, PhD, David T. Burke, PhD, Susan H. Brown, PhD, Paula Anne Newman-Casey, MD

PII: S2589-4196(24)00224-2

DOI: <https://doi.org/10.1016/j.ogla.2024.12.008>

Reference: OGLA 659

To appear in: *OPHTHALMOLOGY GLAUCOMA*

Received Date: 2 April 2024


Revised Date: 17 December 2024

Accepted Date: 23 December 2024

Please cite this article as: Weber MK, Kabil GG, Niziol LM, Urrego DD, Haire C, Cain SM, Sample AP, Burke DT, Brown SH, Newman-Casey PA, Eye Drop Instillation Success and Hand Function in Adults with Glaucoma: A Pilot Study, *OPHTHALMOLOGY GLAUCOMA* (2025), doi: <https://doi.org/10.1016/j.ogla.2024.12.008>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology



1 **Eye Drop Instillation Success and Hand Function in Adults with Glaucoma: A Pilot Study**

2
3 Madeline K Weber, BS^{1*}, Gül G Kabil, BS^{2*}, Leslie M Niziol, MS³, Daniel Duque Urrego, BSE⁴,
4 Cameron Haire, BSE⁵, Stephen M Cain, PhD⁴, Alanson P Sample, PhD⁵, David T Burke, PhD⁶,
5 Susan H Brown, PhD², Paula Anne Newman-Casey, MD³

6 **co-first authors*

- 7
8 1. University of Michigan Medical School, Ann Arbor, Michigan
9 2. University of Michigan School of Kinesiology, Ann Arbor, Michigan
10 3. Department of Ophthalmology and Visual Sciences, University of Michigan W.K.
11 Kellogg Eye Center, Ann Arbor, Michigan
12 4. West Virginia University Department of Chemical and Biomedical Engineering,
13 Morgantown, West Virginia
14 5. University of Michigan Department of Electrical Engineering and Computer Science,
15 Ann Arbor, Michigan
16 6. University of Michigan Department of Human Genetics, Ann Arbor, Michigan

17
18
19
20
21 Corresponding author: Paula Anne Newman-Casey, MD

22 E-mail: panewman@med.umich.edu

23 University of Michigan Kellogg Eye Center

24 1000 Wall Street

25 Ann Arbor, MI 48105

26
27 Meeting Presentation: Paper presentation at the American Glaucoma Society Annual Meeting,
28 2024; Huntington Beach, CA

29
30 Financial support: National Institute of Biomedical Imaging and Bioengineering (R01EB032328)
31 (all authors); Research to Prevent Blindness (Physician Scientist Award, PANC). The sponsor or
32 funding organization had no role in the design or conduct of this research.

33
34 Conflict of Interest Disclosure: No conflicting relationship exists for any author.

35
36 Key words: hand function, sensorimotor deficits, eye drop instillation success, glaucoma

37
38 Running head: Hand Function and Eye Drop Success in Adults with Glaucoma

Abstract

Purpose: To investigate hand function and eye drop instillation success in adults with and without glaucoma.

Design: Cross-sectional pilot study

Subjects: Adults aged 65+ with glaucoma who use eye drops daily, and adults aged 65+ without glaucoma who do not regularly use eye drops.

Methods: Hand function was evaluated using the Saehan Hydraulic Pinch Gauge, Jamar Hand Dynamometer, Grooved Pegboard Test (GPT), Arthritis Hand Function Tests (AHFT), Semmes-Weinstein Monofilament Test, and a tactile pattern recognition device. Eye drop instillation success was analyzed through videography.

Main Outcome Measures: Proportion of successful eye drop instillation trials assessed by: 1) overall success in getting at least one drop in the eye; 2) average number of drops dispensed; 3) bottle tip contact with the eye, eyelashes, or skin. Hand function measures: mean pinch and grip strength, GPT and AHFT completion times, smallest detected monofilament, tactile pattern identification time and accuracy.

Results: 25 participants with glaucoma and 79 participants without glaucoma were included. There was no difference in the proportion of trials where at least one drop was successfully instilled, disregarding bottle tip contact (glaucoma: 0.95, non-glaucoma: 0.91; $p=0.88$). Participants with glaucoma were more likely to make contact between the bottle tip and the eye, eyelashes, or skin compared to those without (glaucoma: 0.49, non-glaucoma: 0.28; $p=0.01$). Participants with glaucoma dispensed a similar number of drops as those without (glaucoma: 1.37, non-glaucoma: 1.46; $p=0.47$). Participants with glaucoma had significantly reduced pinch strength (glaucoma: 4.8 kg, non-glaucoma 6.1 kg, $p=0.01$), grip strength (glaucoma: 23.4 kg, non-glaucoma: 27.7 kg, $p=0.02$), longer completion times for the GPT (glaucoma: 113.5 seconds, non-glaucoma: 85.5 seconds, $p=0.02$) and specific AHFT tasks of fastening/unfastening buttons (glaucoma: 36.6 seconds, non-glaucoma: 27.7 seconds, $p=0.03$) and pinning/unpinning safety pins (glaucoma: 35.4 seconds, non-glaucoma: 27.3 seconds, $p=0.02$), and worse tactile acuity on monofilament ($p=0.04$) compared to participants without glaucoma.

Conclusions: Despite hand function deficits, in this exploratory pilot study, adults with glaucoma demonstrated eye drop instillation success comparable to those without glaucoma, though with higher rates of bottle tip contact with the eye, skin or eyelashes, suggesting an increased risk of potential eye drop bottle contamination. These findings suggest that though regular practice may help mitigate the effects of hand function deficits on the targeted activity of getting the eye drop in the eye, the deficits may make this activity difficult.

82 **Introduction**

83 Glaucoma is a leading cause of irreversible blindness worldwide.¹ The global prevalence of
84 glaucoma is expected to increase from 76 million cases in 2020 to approximately 111.8 million
85 by 2040 in individuals aged 40-80 years.² The primary management for glaucoma involves the
86 daily application of medicated eye drops to lower intraocular pressure.³ However, adherence to
87 the medication regimen remains a significant challenge, with rates of non-adherence ranging
88 from 30% to 80% among patients.^{4,5} Poor adherence to eye drop medications significantly
89 impairs treatment effectiveness and accelerates disease progression. Notably, adherence rates
90 below 80% are associated with an increased risk of severe visual field deficits and progressive
91 visual field loss.^{6,7}

92 Factors contributing to non-adherence include forgetfulness, side effects, medication
93 costs, and difficulties in instilling eye drops, among others.⁸ Even among individuals attempting
94 to adhere to their prescribed eye drop regimen, a significant portion of adults with glaucoma still
95 face challenges in self-administering their medication.^{9,10} Approximately one third of glaucoma
96 patients are unable to instill a single drop into their eye effectively,¹¹ with older patients facing
97 greater difficulties.¹¹⁻¹⁴ Poor instillation technique may be associated with visual impairments¹⁴
98 and physical limitations,¹⁵ which can interfere with both squeezing the bottle and accurately
99 targeting where the drop lands.

100 Hand function, essential for tasks requiring fine sensorimotor control such as instilling
101 eye drops, is known to decline with age.^{16,17} Given that the average age of onset for glaucoma is
102 66 years,¹⁸ adults with glaucoma may experience age-related declines in hand function, which
103 could affect their ability to administer eye drops. While previous studies have highlighted the
104 instillation challenges faced by adults with glaucoma,^{11,19} there remains a significant gap in

105 understanding how age-related sensorimotor deficits impact the ability to self-administer eye
106 drops.

107 Comparative studies evaluating eye drop instillation success between adults with
108 glaucoma who use chronic daily eye drops and adults without glaucoma who do not use daily
109 eye drops are limited, and are needed in order to understand the hand function learning curve
110 associated with instilling drops. Understanding how hand function declines associated with aging
111 may impact eye drop instillation success could potentially inform how to teach the best
112 techniques to promote successful eye drop instillation when someone is newly diagnosed with
113 glaucoma. A previous study compared eye drop instillation success among visually impaired
114 older adults with either glaucoma or retinal disease, finding that both groups, who regularly used
115 eye drops, faced significant challenges in self-administering their medication.²⁰ To date, only one
116 study has specifically compared eye drop instillation success between older adults with glaucoma
117 who use daily eye drops and adults of similar age without glaucoma who do not use eye drops,²¹
118 which found that the participants with glaucoma had lower rates of successful instillation. Our
119 study seeks to build upon this foundation by comparing hand function and eye drop instillation
120 success between older adults with and without glaucoma. We hypothesize that those with
121 glaucoma will have worse hand function and lower eye drop instillation success than those
122 without glaucoma. We used standardized measures from the motor control literature to assess
123 hand function.²²⁻²⁶ This investigation is exploratory and will generate hypotheses as to how
124 sensorimotor deficits associated with aging may impact eye drop instillation success.

125 **Methods**

126 **Participants**

127 The study sample included 25 adults ≥ 65 years of age with any type of glaucoma using
128 medicated drops, and 79 adults ≥ 65 years of age without glaucoma who do not regularly use eye
129 drops, defined as using eye drops less than once per week. As this was a pilot study, the sample
130 size was based on feasibility, with the primary focus on generating hypotheses for future studies.
131 We excluded individuals with a history of allergic reaction to over-the-counter eye drops and any
132 individuals with glaucoma who did not self-administer their drops. Approval for this study was
133 obtained from the Michigan Medicine Institutional Review Board, and written informed consent
134 was obtained for each participant. The study adhered to all the tenets of the Declaration of
135 Helsinki. All participants were recruited from the University of Michigan research participant
136 registry (<https://umhealthresearch.org>) and via community and university flyer postings.
137 Participants were not recruited from eye clinics.

138 **Standardized Assessments**

139 Participants completed standardized assessments of visual acuity, physical activity, grip and
140 pinch strength, dexterity, and tactile registration. Visual acuity was evaluated using a
141 standardized Snellen Chart, and better-eye scores were converted to logMAR for analysis.
142 Participants were assessed for physical activity using the Physical Activity Scale for the Elderly
143 (PASE).²⁷ Grip and three-point pinch strength were measured three times each in the dominant
144 hand using a Jamar Hand Dynamometer and a Saehan Hydraulic Pinch Gauge. Assessments of
145 dexterity included both the Jamar Grooved Pegboard Test (GPT) and the Arthritis Hand Function
146 Test (AHFT). The GPT, one of many pegboard tests, is a commonly used standardized test of
147 manual dexterity²⁸ that is particularly effective in correlating with activities of daily living and
148 quantifying changes in hand function among older adults.²²⁻²⁴ In this test, participants are timed

149 while using their dominant hand to manipulate grooved pegs into a board with holes of varied
150 orientations. The AHFT, originally designed for patients with arthritis and related conditions,
151 includes simulated functional tasks that are commonly encountered in daily life, such as lacing
152 shoes and buttoning clothing. This test was selected because it requires the dexterous use of both
153 hands, a skill required for eye drop bottle use.^{25,26} In this test, participants were timed while
154 completing bimanual simulated activities of daily living, including buttoning a button board,
155 lacing up a shoe and tying a bow, pinning safety pins to fabric, placing coins into a slot, and
156 cutting a piece of clay with a fork and knife. Tactile registration was assessed in the index and
157 ring finger of the dominant hand using the Semmes-Weinstein Monofilament Test (SWMT).²⁹ In
158 the SWMT, participants were asked to close their eyes while monofilaments of various sizes
159 were applied to their finger pads and indicate when they perceived a touch. The smallest
160 detectable monofilament size was recorded for each finger.

161 **Experimental Assessments**

162 *Tactile Discrimination*

163 Tactile discrimination was evaluated using a custom-designed pattern recognition device. While
164 seated in front of the device, participants were given five seconds to feel a visually concealed
165 pattern of raised dots with one finger. After five seconds, participants removed their finger from
166 the pattern and used a touchscreen display to select the pattern they felt from a choice of four
167 patterns. Participants completed four trials each with their dominant index and ring finger, for a
168 total of eight trials in the dominant hand. Patterns were randomly selected for each trial from a

169 set of twelve unique patterns. Outcome measures included the amount of time taken to identify
170 the perceived pattern and accuracy rate of correct identifications.

171 *Assessment of Eye Drop Instillation*

172 Participants completed three eye drop instillation trials for each eye across three different
173 postural configurations (seated, standing, and supine), starting with the right eye in each position.
174 During each trial, participants were instructed to administer one eye drop into their eye,
175 dispensing as many drops as needed to achieve this goal. Participants used a 15 mL bottle of
176 Refresh Tears Lubricant Eye Drops (Allergan, Irvine, CA, USA) for all trials. No instruction was
177 provided for instillation technique; participants self-selected which hand they preferred to hold
178 the bottle with, whether they used their other hand for support, and whether they used a mirror
179 during instillation. Trials were recorded using an iPod touch (7th generation) with high-definition
180 video (8-megapixel camera with 1080p HD video recording). The camera was positioned close
181 to the side of the participant's eye for clear visualization. The video recordings were transferred
182 to a laptop computer for review. The recordings were carefully reviewed by pausing, zooming in
183 and, when necessary, slowing down the footage frame by frame to accurately assess the number
184 of drops dispensed and determine if the trial was successful. Each trial video was reviewed by a
185 research associate who did not take the video recording, though they were not masked to
186 participant glaucoma status. The following measures were collected and managed in a secure
187 research database (UM1TR004404)^{30,31}: location of eye drop instillation, number of drops used
188 to instill one drop, and whether the tip of the eye drop bottle touched the ocular surface,
189 eyelashes, or skin. In rare cases where the solution was dispensed as a stream instead of
190 individual drops, it was counted as four drops if a clear start and end of the stream could be

191 determined. A single research associate reviewed each video. To assess the reliability of the eye
192 drop instillation success measures graded from videos (location of eye drop, number of drops
193 dispensed, bottle tip contact with the ocular surface, skin, or eyelashes), a 10% random sample of
194 videos were selected stratified by grader, position, and eye, with an oversampling of videos
195 where more than one eye drop was dispensed. This sample was re-graded by additional research
196 associates masked to the initial grading. Inter-grader agreement of measures obtained from
197 videos was good and ranged from 86.9% to 95.6% (Supplemental Table 1).

198 **Statistical Analysis**

199 Characteristics of the sample (participant demographics, eye drop instillation success,
200 sensorimotor function) were summarized with descriptive statistics, including mean and standard
201 deviation for continuous measures and frequency and percentage for categorical measures. Six
202 measures of eye drop installation success were calculated, aggregated over all 18 trials, including
203 1) proportion of trials with no bottle tip contact with the eye, eyelashes, or skin, 2) proportion of
204 trials with only one drop dispensed, 3) mean number of drops dispensed to instill a single drop,
205 4) proportion of trials with at least one drop successfully placed in the eye, 5) proportion of trials
206 with at least one drop successfully placed in the eye with no bottle tip contact, and 6) proportion
207 of trails with exactly one drop successfully placed in the eye with no bottle tip contact.

208 Participants with and without glaucoma were compared for differences in demographic
209 characteristics, eye drop installation success, and sensorimotor function with 2-sample t-tests (for
210 normally distributed continuous measures), 2-sample Wilcoxon tests (for non-normally
211 distributed continuous measures), Chi-square tests (for categorical measures with expected
212 counts ≥ 5), or Fisher's exact tests (for categorical measures with expected counts < 5). Linear

213 regression was used to estimate the differences in eye drop success and sensorimotor function
214 between participants with and without glaucoma, adjusting for age and diabetes. Model results
215 are reported with regression estimates and 95% confidence intervals (CI). Due to the limited
216 variability in monofilament detection in the sample, models adjusted for age and diabetes could
217 not be performed for this outcome. SAS version 9.4 (SAS Institute, Cary NC) was used for all
218 statistical analysis.

219 **Results**

220 A total of 25 glaucoma participants and 79 participants without glaucoma were
221 studied. Participants with glaucoma reported using 1 (n=9, 36.0%), 2 (n=11, 44.0%), or 3 (n=5,
222 20.0%) daily eye drop medications to control their disease, for durations that were less than 1
223 year (n=1, 4.0%), 1-5 years (n=10, 40.0%), 6-10 years (n=7, 28.0%), or >10 years (n=7,
224 28.0%). Those without glaucoma reported using over the counter eye drops either weekly (n=6,
225 7.6%), monthly (n=11, 13.9%), rarely (n=31, 39.2%), or never (n=31, 39.2%). Glaucoma
226 participants (n=25) had significantly worse vision than non-glaucoma participants (n=79).
227 Specifically, glaucoma participants had average logMAR visual acuity of 0.45 (Snellen
228 equivalent 20/57; median 20/30), whereas non-glaucoma participants had average logMAR
229 visual acuity of 0.12 (Snellen equivalent 20/26; median 20/25), $p=0.0007$. No significant
230 demographic differences were found between participants with versus without glaucoma for age
231 (mean of 75.3 years [SD=1.8] vs 73.3 years [SD=5.8], $p=0.15$), sex (45.8% male vs 44.9,
232 $p=0.93$), race (80.0% White vs 85.5%, $p=0.50$), ethnicity (0.0% Hispanic vs 1.3%, $p=1.00$),
233 education ($p=0.42$), and income ($p=0.81$) (Table 2). Further, no significant difference between
234 groups was found with respect to physical activity (mean PASE score 150.6 [SD=73.7] vs 155.7

235 [SD=73.3], $p=0.76$). However, a larger percentage of glaucoma participants reported having
236 diabetes than participants without glaucoma (20.8% vs 5.1%, $p=0.03$). For the reduced sample
237 with tactile measures, no significant demographic differences were observed between those with
238 and without glaucoma (Supplemental Table 3).

239 Participants showed differing success with eye drop instillation measures (Table 4).
240 Bottle tip contact with the eye, eyelashes, or skin was the largest hurdle to successful eye drop
241 instillation with an average rate of non-contact of 0.51 for glaucoma participants (SD=0.55,
242 median=0.67), which was significantly worse than the average rate of 0.72 for participants
243 without glaucoma (SD=0.36, median=0.94; $p=0.01$; Figure 1A). The rate of dispensing only one
244 drop from the bottle was similar between glaucoma (mean=0.76, SD=0.17, median=0.78) and
245 non-glaucoma groups (mean=0.72, SD=0.23, median=0.72; $p=0.59$; Figure 1B). There was no
246 difference in the number of drops dispensed to successfully instill a single drop in the eye among
247 those with and without glaucoma (glaucoma: mean=1.37, SD=0.31, median=1.28; non-
248 glaucoma: mean=1.46, SD=0.41; median=1.39; $p=0.47$; Figure 1C). The average proportion of
249 trials that glaucoma participants successfully placed at least one drop in their eye was high at
250 0.95 (SD=0.07, median=0.94), which was similar to the average proportion for participants
251 without glaucoma of 0.91 (SD=0.17, median=1.00; $p=0.88$; Figure 1D). However, when
252 accounting for bottle tip contact, these rates decreased and were significantly different between
253 groups such that those with glaucoma had an average rate of instilling at least one drop in the eye
254 without contacting the bottle tip of 0.49 (SD=0.42, median=0.56) compared to 0.68 for those
255 without glaucoma (SD=0.36, median=0.83; $p=0.03$; Figure 1E). These rates reduced further when
256 also requiring only a single drop be instilled, although no significant difference was observed
257 between those with and without glaucoma (glaucoma: mean=0.39, SD=0.36, median=0.44; non-

258 glaucoma: mean=0.53, SD=0.34, median=0.56; p=0.06; Figure 1F) After adjusting for age and
259 diabetes status, though the directionality of the estimated differences in instillation success
260 between participants with and without glaucoma remained the same, the results were no longer
261 statistically significant (Table 5).

262 Several differences in sensorimotor function were observed between participants with
263 and without glaucoma (Table 4). Participants with versus without glaucoma showed significantly
264 reduced pinch force (mean of 4.8 kg [SD=4.8] vs 6.1 kg [SD=2.1], p=0.01, Figure 2A) and grip
265 strength (mean of 23.4 kg [SD=10.7] vs 27.7 kg [SD=10.6], p=0.02, Figure 2B). Additionally,
266 participants with glaucoma took significantly longer than those without glaucoma to complete
267 the GPT (mean of 113.5 seconds [SD=52.3] vs 85.5 seconds [SD=23.4], p=0.02, Figure 2C) and
268 individual activities from the AHFT including fastening/unfastening 4 buttons (mean of 36.6
269 seconds [SD=19.0] vs 27.7 seconds [SD=8.2], p=0.03), and pinning/unpinning 2 safety pins
270 (mean of 35.4 seconds vs 27.3 seconds [SD=7.4], p=0.02, Figure 2D). No significant differences
271 were observed between participants with and without glaucoma for time to complete the tasks of
272 lacing a shoe and tying a bow, picking up and manipulating 4 coins into a slot, and cutting putty
273 into 4 pieces with a knife (all p>0.05, Table 4). A significantly smaller percentage of participants
274 with glaucoma were able to detect the smallest monofilaments compared to those without
275 glaucoma (2.83 monofilament: 8.0% vs 20.3%; 3.61 monofilament: 67.0% vs 77.2%; p=0.04;
276 Figure 2E). Lastly, there was also a marginally significant difference in time to complete tactile
277 testing (Figure 2F) where those with glaucoma took longer than those without glaucoma (mean
278 of 5.1 seconds [SD=2.3] vs 4.2 seconds [SD=1.9], p=0.10), but there was no difference in tactile
279 accuracy (mean of 43.7% accurate [SD=24.1] vs 52.1% [SD=20.9], p=0.20, Table 4).

280 After adjusting for age and diabetes status, differences between participants with and
281 without glaucoma on sensorimotor function measurements remained significant or remained with
282 a trend in the hypothesized direction (Table 5). Participants with glaucoma were estimated to
283 have weaker pinch force than participants without glaucoma by 0.9 kg (95% CI: -1.9 to 0.1,
284 $p=0.07$), took 22.7 seconds longer complete the GPT (95% CI: 8.2 to 37.3, $p=0.003$), and took
285 1.0 second longer to complete tactile testing (95% CI: -0.1 to 2.1, $p=0.08$). Participants with
286 glaucoma also took longer to complete the AHFT, including an estimated additional 6.6 seconds
287 to finish fastening/unfastening 4 buttons (95% CI: 1.2 to 12.1, $p=0.02$), an additional 5.6 seconds
288 to finish lacing a shoe and tying a bow (95% CI: -0.7 to 11.9, $p=0.08$), and an additional 7.4
289 seconds to finish pinning/unpinning 2 safety pins (95% CI: 2.3 to 12.6, $p=0.005$).

290 **Discussion**

291 In this study, we explored specific hand function testing and eye drop instillation success among
292 adults with glaucoma who regularly use medicated eye drops compared to adults without
293 glaucoma who do not use eye drops regularly. Though we had hypothesized that people with
294 glaucoma would have worse hand function and lower success instilling eye drops compared to
295 people without glaucoma, we did not find this in our study. We found that although participants
296 with glaucoma had reduced hand function including decreased grip and pinch strength, decreased
297 manual dexterity, and decreased tactile acuity compared to adults who do not use eye drops
298 regularly, they achieved similar success in eye drop instillation as the non-glaucoma participants,
299 though with a higher incidence of bottle tip contact with the eye, skin or eyelashes, suggesting an
300 increased risk of potential bottle contamination.

301 These findings suggest that the individuals with glaucoma may have developed adaptive
302 strategies to compensate for their hand function deficits, potentially through the routine and

303 repetitive task of daily eye drop use. Among glaucoma participants in our study, 96% had been
304 using drops for over a year, and 56% for over six years. It may be possible that regular practice
305 of the specific task of eye drop instillation over time enables refinement of skills compared to
306 other activities involving precise control of hand movements. While the transfer of motor skill
307 learning from one arm to the other has been demonstrated,³² it has also been demonstrated that
308 the generalizability of more complex movements involving the coordination of different joints is
309 poor^{33,34} and independent of the intensity of training.³⁵ This literature suggests that learning to do
310 a very specific task well, like instilling eye drops, may not generalize to being able to do other
311 tasks requiring good hand function well. These observations support earlier work demonstrating
312 that transfer of motor skill learning is most effective when tasks share similar joint
313 configurations³⁶ rather than end-point control of body segments, as in what is necessary to hold
314 the eye drop bottle above the eye and dispense a drop. Thus, in the present study, the ability to
315 successfully instill an eye drop in the eye despite poor hand function may be an example of non-
316 transferable task-specific training.

317 The question remains, however, as to why glaucoma patients had poor hand function on
318 standardized measures of dexterity. Both the grooved pegboard test and the arthritis hand
319 function test require visual monitoring of hand movements. Although research on hand function
320 in the glaucoma population is limited, prior research suggests that adults with glaucoma may
321 experience impaired eye-hand coordination compared to adults without glaucoma.^{37,38} Of
322 particular interest, Zwierko et al.³⁷ found that adults with moderate to advanced glaucoma
323 exhibited eye-hand coordination deficits that could not be entirely attributed to visual field
324 defects. They suggested that other factors, such as accelerated age-related changes in visuomotor
325 processing and reduced physical activity, may be contributing to these findings. While previous

326 research suggests that adults with glaucoma are less physically active than their non-glaucoma
327 counterparts,³⁹ our study found no significant differences in overall physical activity levels
328 between the two groups, though our measure of physical activity was through self-report. The
329 participants with glaucoma did have significantly worse visual acuity than the participants
330 without glaucoma. Poor visual acuity in adults with glaucoma has been associated with restricted
331 participation in activities of daily living,⁴⁰ many of which require skilled hand use. A reduction in
332 hand use over time could contribute to diminished hand strength and dexterity, potentially
333 leading to difficulties in tasks requiring fine sensorimotor control, such as manipulating an eye
334 drop bottle. It is thus reasonable to hypothesize that the impaired hand function observed in the
335 glaucoma group may reflect a decline in overall hand use due to impairments in visual acuity.
336 This impaired hand function may be why we see an increase in bottle tip contact among those
337 with glaucoma alongside the increased success in getting a drop in the eye.

338 Previous studies have highlighted the challenges faced by adults with glaucoma in self-
339 administering eye drops. A review of 15 observational studies indicates that up to 61% of
340 glaucoma patients struggle to dispense the correct dosage of one drop, as many as 37% miss the
341 eye entirely, and up to 80% contaminate their eye drop bottles.⁹ A study by Naito et al.²¹
342 compared eye drop instillation success, defined as the deposition of one drop onto the ocular
343 surface on the first attempt without any bottle tip contact with the eye, skin or eyelashes, between
344 volunteers with and without glaucoma. They found that the adults with glaucoma had lower
345 success rates (38.5%) compared to adults without glaucoma (56.5%). Using a similar definition
346 of success, we observed a marginally significant difference between groups in the proportion of
347 trials with instillation of only one drop into the eye and no contact between the bottle tip and eye
348 or ocular adnexae (glaucoma: 0.39, non-glaucoma: 0.53; $p=0.06$). When success was defined less

349 stringently as the instillation of one or more drops into the eye and no eye drop bottle tip contact,
350 the glaucoma group had significantly fewer successful trials (glaucoma: 0.49, non-glaucoma:
351 0.68; $p=0.03$). Under our broadest definition of success, getting at least one drop into the eye
352 irrespective of eye drop bottle tip contact, both groups had similar success (glaucoma: 0.95, non-
353 glaucoma: 0.91; $p=0.88$). Potential contamination of the bottle tip through contact with the eye or
354 ocular adnexae was more prevalent among the glaucoma participants, with a smaller proportion
355 of their trials having no contact (glaucoma: 0.51, non-glaucoma: 0.72; $p=0.013$). While regular
356 practice of instilling eye drops daily may enable glaucoma participants to administer drops
357 successfully, their ability to perform the finer movements necessary to prevent bottle tip contact
358 may be impaired by their reduced hand function.

359 Both groups demonstrated comparable success in instilling at least one drop into their
360 eye. Participants with glaucoma used an average of 1.37 drops, and non-glaucoma participants
361 used an average of 1.46 drops to successfully instill a single drop into their eye, and this
362 difference was not statistically significant ($p=0.47$). Although the excess usage beyond a single
363 drop for both groups may appear minor, it translates into notable medication waste over time,
364 particularly for patients requiring multiple daily instillations. This can result in a shortage before
365 the next refill is available that will be covered by insurance, leading people to pay out of pocket
366 for the medication or have a gap in eye drop usage. Further, this study used a 15mL artificial tear
367 bottle, that was likely more pliable and easier to squeeze than many of the bottles of glaucoma
368 medications, which likely underestimated difficulties with eye drop instillation. Several
369 researchers have demonstrated that the force required to squeeze the different glaucoma
370 medication bottles is highly variable, based on bottle shape, pliability of the bottle material,
371 orientation of the bottle, and the number of drops left in the bottle.^{41,42} Drew and Wolffsohn

372 demonstrated that average pinch grip strength among people with glaucoma was not always
373 sufficiently forceful to dispense a drop from the glaucoma medication bottle, leading them to
374 conclude that many glaucoma patients likely struggle with the force required to dispense an eye
375 drop from several of the bottle designs.⁴¹

376 Considering that hand function continues to decline with advancing age,⁴³ there may be a
377 threshold at which the combined effects of hand function deficits and vision loss from glaucoma
378 significantly impair the ability to administer eye drops, thereby affecting the overall
379 effectiveness of the treatment. This highlights the need for developing targeted interventions to
380 address instillation challenges, particularly for individuals newly diagnosed with glaucoma, those
381 aged 65 and older who are more likely to experience motor control deficits, and anyone with
382 decreased hand function. Furthermore, as hand function continues to decline with age, it brings
383 to light the potential that targeted interventions to improve hand function overall might impact
384 not only the ability to instill eye drops, but also the ability to engage with more activities of daily
385 living. Additionally, identifying older patients with hand function deficits who may struggle with
386 eye drop instillation could help guide clinicians toward considering alternative treatment options
387 such as selective laser trabeculoplasty (SLT) or surgical interventions, which may reduce the
388 drop burden for patients who have difficulty utilizing topical medications.

389 The strengths of this study include its targeted focus on older adults and the prospective
390 assessment of hand function using standardized methods. Our study has limitations. Given its
391 exploratory nature, no sample size calculations were conducted, and the study was not powered
392 to detect differences across all outcomes. Because this is a pilot study, the results should be seen
393 as hypothesis generating rather than hypothesis testing. Eye drop instillation success was
394 assessed using artificial tear bottles, which typically require less squeezing force than glaucoma

395 medication bottles. The artificial tear bottles utilized in this study had a volume of 15 mL, in
396 contrast to the average 5 mL volume of typical glaucoma medication bottles, which could result
397 in the artificial tear bottles being more pliable and underestimating the difficulty people may
398 have instilling glaucoma medication. We did not assess whether non-glaucoma participants faced
399 limitations that would prevent them from self-administering eye drops, an exclusion criterion for
400 the glaucoma participants. Consequently, the glaucoma group may consist of individuals more
401 adept at administering their own drops, while the non-glaucoma group could include those who
402 require assistance. There were few instances where participants dispensed a stream of eye drops
403 and the number of drops were not countable, and so we counted these instances as four drops,
404 this involved 2.4% of the 1979 trials. Contrast sensitivity was not assessed, which could have
405 provided further insight into the visual factors affecting hand function. The accessibility of this
406 study was limited to individuals able to drive to the research location, potentially introducing a
407 healthy volunteer bias into our findings, though this would be present across both groups.
408 Additionally, participants were recruited from a restricted geographic area characterized by high
409 income and education levels, which does not reflect the broader population. Future studies
410 should address whether these differences exist in more diverse settings.

411 Our study highlights the critical need to understand the factors that contribute to
412 successful eye drop instillation, with a particular focus on hand function deficits that may impact
413 one's ability to effectively administer eye drops. Such information could be utilized to develop
414 personalized and timely educational interventions aimed at refining eye drop instillation
415 techniques particularly among those newly diagnosed with glaucoma. However, with projected
416 workforce shortages among ophthalmologists,⁴⁴ combined with the aging US population and
417 subsequent increasing prevalence of glaucoma,² ophthalmologists may be constrained in their

418 ability to provide such instruction. Novel strategies are needed to address this gap in glaucoma
419 care. By standardizing assessment and coaching techniques, perhaps ophthalmic technicians
420 could play a crucial role in filling this gap. Additionally, through standardized assessment, those
421 with difficulties instilling eye drops could be identified and potentially referred to occupational
422 therapy for additional coaching and strengthening and/or the physician could identify alternative
423 approaches for intraocular pressure management.

424

Journal Pre-proof

References

- 425
426
427 1. Causes of blindness and vision impairment in 2020 and trends over 30 years, and
428 prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for
429 the Global Burden of Disease Study. *Lancet Glob Health*. Feb 2021;9(2):e144-e160.
430 doi:10.1016/s2214-109x(20)30489-7
- 431 2. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of
432 glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-
433 analysis. *Ophthalmology*. Nov 2014;121(11):2081-90. doi:10.1016/j.ophtha.2014.05.013
- 434 3. Gedde SJ, Vinod K, Wright MM, et al. Primary Open-Angle Glaucoma Preferred Practice
435 Pattern®. *Ophthalmology*. Jan 2021;128(1):P71-p150. doi:10.1016/j.ophtha.2020.10.022
- 436 4. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular
437 hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based
438 review. *Ophthalmology*. Jun 2005;112(6):953-61. doi:10.1016/j.ophtha.2004.12.035
- 439 5. Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. *Surv*
440 *Ophthalmol*. Nov 2008;53 Suppl1:S57-68. doi:10.1016/j.survophthal.2008.08.002
- 441 6. Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication
442 adherence, eye drop technique, and visual field defect severity. *Ophthalmology*. Dec
443 2011;118(12):2398-402. doi:10.1016/j.ophtha.2011.05.013
- 444 7. Newman-Casey PA, Niziol LM, Gillespie BW, Janz NK, Lichter PR, Musch DC. The
445 Association between Medication Adherence and Visual Field Progression in the Collaborative
446 Initial Glaucoma Treatment Study. *Ophthalmology*. Apr 2020;127(4):477-483.
447 doi:10.1016/j.ophtha.2019.10.022
- 448 8. Newman-Casey PA, Robin AL, Blachley T, et al. The Most Common Barriers to
449 Glaucoma Medication Adherence: A Cross-Sectional Survey. *Ophthalmology*. Jul
450 2015;122(7):1308-16. doi:10.1016/j.ophtha.2015.03.026
- 451 9. Davis SA, Sleath B, Carpenter DM, Blalock SJ, Muir KW, Budenz DL. Drop instillation
452 and glaucoma. *Curr Opin Ophthalmol*. Mar 2018;29(2):171-177.
453 doi:10.1097/icu.0000000000000451
- 454 10. Tsai T, Robin AL, Smith JP, 3rd. An evaluation of how glaucoma patients use topical
455 medications: a pilot study. *Trans Am Ophthalmol Soc*. 2007;105:29-33; discussion 33-5.
- 456 11. Hennessy AL, Katz J, Covert D, Protzko C, Robin AL. Videotaped evaluation of eyedrop
457 instillation in glaucoma patients with visual impairment or moderate to severe visual field loss.
458 *Ophthalmology*. Dec 2010;117(12):2345-52. doi:10.1016/j.ophtha.2010.03.040
- 459 12. Kholdebarin R, Campbell RJ, Jin YP, Buys YM. Multicenter study of compliance and
460 drop administration in glaucoma. *Can J Ophthalmol*. Aug 2008;43(4):454-61. doi:10.1139/i08-
461 076
- 462 13. Tatham AJ, Sarodia U, Gatrads F, Awan A. Eye drop instillation technique in patients with
463 glaucoma. *Eye (Lond)*. Nov 2013;27(11):1293-8. doi:10.1038/eye.2013.187
- 464 14. Dietlein TS, Jordan JF, Lüke C, Schild A, Dinslage S, Krieglstein GK. Self-application of
465 single-use eyedrop containers in an elderly population: comparisons with standard eyedrop bottle
466 and with younger patients. *Acta Ophthalmol*. Dec 2008;86(8):856-9. doi:10.1111/j.1755-
467 3768.2007.01155.x
- 468 15. Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes of non-
469 compliance by patients prescribed eyedrops. *Br J Ophthalmol*. Aug 1990;74(8):477-80.
470 doi:10.1136/bjo.74.8.477

- 471 16. Ranganathan VK, Siemionow V, Sahgal V, Yue GH. Effects of aging on hand function. *J*
472 *Am Geriatr Soc.* Nov 2001;49(11):1478-84. doi:10.1046/j.1532-5415.2001.4911240.x
- 473 17. Carmeli E, Patish H, Coleman R. The aging hand. *J Gerontol A Biol Sci Med Sci.* Feb
474 2003;58(2):146-52. doi:10.1093/gerona/58.2.m146
- 475 18. Kolko M, Horwitz A, Thygesen J, Jeppesen J, Torp-Pedersen C. The Prevalence and
476 Incidence of Glaucoma in Denmark in a Fifteen Year Period: A Nationwide Study. *PLoS One.*
477 2015;10(7):e0132048. doi:10.1371/journal.pone.0132048
- 478 19. Stone JL, Robin AL, Novack GD, Covert DW, Cagle GD. An objective evaluation of
479 eyedrop instillation in patients with glaucoma. *Arch Ophthalmol.* Jun 2009;127(6):732-6.
480 doi:10.1001/archophthalmol.2009.96
- 481 20. Hennessy AL, Katz J, Covert D, et al. A video study of drop instillation in both glaucoma
482 and retina patients with visual impairment. *Am J Ophthalmol.* Dec 2011;152(6):982-8.
483 doi:10.1016/j.ajo.2011.05.015
- 484 21. Naito T, Namiguchi K, Yoshikawa K, et al. Factors affecting eye drop instillation in
485 glaucoma patients with visual field defect. *PLoS One.* 2017;12(10):e0185874.
486 doi:10.1371/journal.pone.0185874
- 487 22. Marmon AR, Pascoe MA, Schwartz RS, Enoka RM. Associations among strength,
488 steadiness, and hand function across the adult life span. *Med Sci Sports Exerc.* Apr
489 2011;43(4):560-7. doi:10.1249/MSS.0b013e3181f3f3ab
- 490 23. Hamilton LD, Thomas E, Almklass AM, Enoka RM. A framework for identifying the
491 adaptations responsible for differences in pegboard times between middle-aged and older adults.
492 *Exp Gerontol.* Oct 15 2017;97:9-16. doi:10.1016/j.exger.2017.07.003
- 493 24. Heintz Walters B, Huddleston WE, O'Connor K, Wang J, Hoeger Bement M, Keenan KG.
494 The role of eye movements, attention, and hand movements on age-related differences in
495 pegboard tests. *J Neurophysiol.* Nov 1 2021;126(5):1710-1722. doi:10.1152/jn.00629.2020
- 496 25. Backman C, Mackie H. Arthritis hand function test: inter-rater reliability among self-
497 trained raters. *Arthritis Care Res.* Mar 1995;8(1):10-5. doi:10.1002/art.1790080105
- 498 26. Poole JL. Measures of hand function: Arthritis Hand Function Test (AHFT), Australian
499 Canadian Osteoarthritis Hand Index (AUSCAN), Cochin Hand Function Scale, Functional Index
500 for Hand Osteoarthritis (FIHOA), Grip Ability Test (GAT), Jebsen Hand Function Test (JHFT),
501 and Michigan Hand Outcomes Questionnaire (MHQ). *Arthritis Care Res (Hoboken).* Nov
502 2011;63 Suppl 11:S189-99. doi:10.1002/acr.20631
- 503 27. Washburn RA, McAuley E, Katula J, Mihalko SL, Boileau RA. The physical activity
504 scale for the elderly (PASE): evidence for validity. *J Clin Epidemiol.* Jul 1999;52(7):643-51.
505 doi:10.1016/s0895-4356(99)00049-9
- 506 28. Reuben DB, Magasi S, McCreath HE, et al. Motor assessment using the NIH Toolbox.
507 *Neurology.* Mar 12 2013;80(11 Suppl 3):S65-75. doi:10.1212/WNL.0b013e3182872e01
- 508 29. Bell-Krotoski J, Weinstein S, Weinstein C. Testing sensibility, including touch-pressure,
509 two-point discrimination, point localization, and vibration. *J Hand Ther.* Apr-Jun 1993;6(2):114-
510 23. doi:10.1016/s0894-1130(12)80292-4
- 511 30. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
512 capture (REDCap)--a metadata-driven methodology and workflow process for providing
513 translational research informatics support. *J Biomed Inform.* Apr 2009;42(2):377-81.
514 doi:10.1016/j.jbi.2008.08.010

- 515 31. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international
516 community of software platform partners. *J Biomed Inform.* Jul 2019;95:103208.
517 doi:10.1016/j.jbi.2019.103208
- 518 32. Yadav G, Mutha PK. Symmetric interlimb transfer of newly acquired skilled movements.
519 *J Neurophysiol.* Nov 1 2020;124(5):1364-1376. doi:10.1152/jn.00777.2019
- 520 33. Krishnan C, Ranganathan R, Tetarbe M. Interlimb transfer of motor skill learning during
521 walking: No evidence for asymmetric transfer. *Gait Posture.* Jul 2017;56:24-30.
522 doi:10.1016/j.gaitpost.2017.04.032
- 523 34. Giboin LS, Gruber M, Kramer A. Task-specificity of balance training. *Hum Mov Sci.* Dec
524 2015;44:22-31. doi:10.1016/j.humov.2015.08.012
- 525 35. Boutin A, Badets A, Salesse RN, Fries U, Panzer S, Blandin Y. Practice makes transfer of
526 motor skills imperfect. *Psychol Res.* Sep 2012;76(5):611-25. doi:10.1007/s00426-011-0355-2
- 527 36. Malfait N, Shiller DM, Ostry DJ. Transfer of motor learning across arm configurations. *J*
528 *Neurosci.* Nov 15 2002;22(22):9656-60. doi:10.1523/jneurosci.22-22-09656.2002
- 529 37. Zwierko T, Jedziniak W, Lesiakowski P, Śliwiak M, Kirkiewicz M, Lubiński W. Eye-
530 Hand Coordination Impairment in Glaucoma Patients. *Int J Environ Res Public Health.* Nov 7
531 2019;16(22)doi:10.3390/ijerph16224332
- 532 38. Kotecha A, O'Leary N, Melmoth D, Grant S, Crabb DP. The functional consequences of
533 glaucoma for eye-hand coordination. *Invest Ophthalmol Vis Sci.* Jan 2009;50(1):203-13.
534 doi:10.1167/iovs.08-2496
- 535 39. Olszewska H, Kosny J, Jurowski P, Jegier A. Physical activity of patients with a primary
536 open angle glaucoma. *Int J Ophthalmol.* 2020;13(7):1102-1108. doi:10.18240/ijo.2020.07.14
- 537 40. Noe G, Ferraro J, Lamoureux E, Rait J, Keeffe JE. Associations between glaucomatous
538 visual field loss and participation in activities of daily living. *Clin Exp Ophthalmol.* Dec
539 2003;31(6):482-6. doi:10.1046/j.1442-9071.2003.00712.x
- 540 41. Drew T, Wolffsohn JS. Usability of prostaglandin monotherapy eye droppers. *Br J*
541 *Ophthalmol.* Sep 2015;99(9):1251-4. doi:10.1136/bjophthalmol-2014-306291
- 542 42. Moore DB, Hammer JD, Akhtari R, Beck J, Sanders S, Kryscio RJ. Squeeze Me if You
543 Can: Variability in Force Requirements to Extract a Drop From Common Glaucoma Bottles. *J*
544 *Glaucoma.* Sep 2016;25(9):780-4. doi:10.1097/ijg.0000000000000506
- 545 43. Shiffman LM. Effects of aging on adult hand function. *Am J Occup Ther.* Sep
546 1992;46(9):785-92. doi:10.5014/ajot.46.9.785
- 547 44. Berkowitz ST, Finn AP, Parikh R, Kuriyan AE, Patel S. Ophthalmology Workforce
548 Projections in the United States, 2020 to 2035. *Ophthalmology.* Feb 2024;131(2):133-139.
549 doi:10.1016/j.ophtha.2023.09.018

550

551

552 **Figure captions**

553

554 Figure 1. Boxplots displaying the distribution of eye drop installation success measures, stratified
555 by glaucoma status, including A) proportion of trials with no eye drop bottle tip contact with the
556 eye, eyelashes, or skin, B) proportion of trials with only one drop dispensed, C) mean number of
557 drops dispensed to instill a single drop, D) proportion of trials with at least one drop successfully
558 placed in the eye, E) proportion of trials with at least one drop successfully placed in the eye
559 with no bottle tip contact, and F) proportion of trails with exactly one drop successfully placed in
560 the eye with no bottle tip contact.

561 Figure 2. Plots (boxplots and bar chart) displaying the distribution of motor function measures,
562 stratified by glaucoma status, including A) Pinch force, B) Grip strength, C) Time to complete
563 the grooved pegboard test, D) Time to complete the arthritis hand function pinning/unpinning 4
564 safety pins test, E) Smallest monofilament detected with the index finger of the dominant hand,
565 and F) Median time to complete tactile testing.

566

Table 2. Sample descriptives stratified by glaucoma status


Continuous Variable	Glaucoma (n=25)		No Glaucoma (n=79)		P-value ^a
	Mean (SD)	Median	Mean (SD)	Median	
Age (years)	75.3 (6.2)	74.0	73.3 (5.8)	72.0	0.1503
PASE Score	150.6 (73.7)	147.0	155.7 (73.3)	151.0	0.7623
Categorical Variable	Frequency (Percent)		Frequency (Percent)		P-value ^b
Sex - Male	11 (45.8)		35 (44.9)		
Race					
White	20 (80.0)		65 (85.5)		0.5043
Black	4 (16.0)		6 (7.9)		
Asian	1 (4.0)		5 (6.6)		
Ethnicity - Hispanic/Latino	0 (0.0)		1 (1.3)		1.0000
Education					
High School/GED	3 (12.0)		2 (2.5)		0.4201
Vocational/Technical	0 (0.0)		1 (1.3)		
Some College/Associate Degree	5 (20.0)		15 (19.0)		
College Graduate	7 (28.0)		25 (31.7)		
Graduate/Professional Degree	10 (40.0)		36 (45.6)		
Income					
<\$20k	1 (4.6)		3 (4.4)		0.8059
\$20k-\$39k	3 (13.6)		14 (20.3)		
\$40k-\$59k	3 (13.6)		8 (11.6)		
\$60k-\$79k	2 (9.1)		8 (11.6)		
\$80k-\$99k	1 (4.6)		8 (11.6)		
\$100k-\$119k	5 (22.7)		11 (15.9)		
\$120k-\$139k	1 (4.6)		6 (8.7)		
\$140k-\$160k	1 (4.6)		5 (7.3)		
>\$160k	5 (22.7)		6 (8.7)		
Handed					
Right-handed	22 (88.0)		70 (88.6)		0.8674
Left-handed	2 (8.0)		5 (6.3)		
Both	1 (4.0)		4 (5.1)		
Comorbidities					
Cardiac	8 (33.3)		16 (20.8)		0.2071
Vascular	16 (64.0)		37 (48.1)		0.1655
Pulmonary	3 (12.0)		5 (6.4)		0.3981
Neurologic	0 (0.0)		1 (1.3)		1.0000
Endocrine/Diabetes	5 (20.8)		4 (5.1)		0.0314
Renal	3 (12.5)		6 (7.7)		0.4360
Hepatic	0 (0.0)		1 (1.3)		1.0000
Gastrointestinal	0 (0.)		5 (5.1)		0.5704
Mental	1 (4.2)		6 (7.9)		1.0000
Osteoarthritis	16 (66.7)		41 (55.4)		0.3311
Immunocompromised	3 (12.0)		8 (10.3)		0.7257
Blood Disorder	1 (4.0)		1 (1.3)		0.4283

PASE, Physical Activity Score for Elderly; GED, General Education Diploma; ^a2-sample t-test, ^bChi-square or Fisher's exact test; Percentages are reported on the non-missing sample


Outcome	Glaucoma (n=25)				No Glaucoma (n=79)				p-value ^a
	n	Mean	SD	Median	n	Mean	SD	Median	
Eyedrop Installation									
Proportion of trials with no contamination	25	0.51	0.44	0.67	79	0.72	0.36	0.94	0.0128
Proportion of trials with only 1 drop dispensed	25	0.76	0.17	0.78	79	0.72	0.23	0.72	0.5899
Average number of drops used to instill one over all trials	25	1.37	0.31	1.28	79	1.46	0.41	1.39	0.4686
Proportion of trials with ≥1 drop in the eye	25	0.95	0.07	0.94	79	0.91	0.17	1.00	0.8829
Proportion of trials with ≥1 drop in the eye & no contamination	25	0.49	0.42	0.56	79	0.68	0.36	0.83	0.0301
Proportion of trials with only 1 drop in the eye & no contamination	25	0.39	0.36	0.44	79	0.53	0.34	0.56	0.0631
Sensorimotor Function									
Median Pinch Force - Dominant Hand (kg)	25	4.8	2.1	5.0	79	6.1	2.1	6.0	0.0098
Median Grip Strength - Dominant Hand (kg)	25	23.4	10.7	20.0	79	27.7	10.6	24.0	0.0185
Time to complete Grooved Pegboard - Dominant Hand (sec)	23	113.4	52.3	93.0	79	85.8	23.4	80.0	0.0166
AHF Fasten/Unfasten 4 buttons (sec)	25	36.6	19.0	30.0	79	27.7	8.2	26.0	0.0324
AHF Lacing shoe and tying bow (sec)	24	49.6	18.1	44.0	79	42.2	12.0	39.0	0.0718
AHF Pinning/Unpinning 2 safety pins (sec)	23	35.4	17.5	32.0	79	27.3	7.4	26.0	0.0214
AHF Picking up/Manipulating 4 coins into a slot (sec)	24	14.4	5.3	12.0	79	12.6	4.6	12.0	0.1510
AHF Cutting putty into 4 pieces with knife (sec)	23	13.3	4.5	12.0	77	12.6	3.5	12.0	0.6924
AHF Sum all times (sec)	23	143.2	49.2	127.0	77	121.3	23.3	120.0	0.0647
Median time to complete tactile testing (sec)	20	5.1	2.3	4.4	41	4.2	1.9	3.9	0.0986
Percent tactile accuracy	20	43.7	24.1	40.2	41	52.1	20.9	50.0	0.1972
		Frequency (Column Percent)				Frequency (Column Percent)			p-value ^b
Smallest Monofilament detected - Index finger, Dominant Hand									
'2.83		0 (0.0)				5 (6.3)			
'3.61		22 (88.0)				70 (88.6)			
'4.31		2 (8.0)				4 (5.1)			0.1761
'4.56		1 (4.0)				0 (0.0)			
Smallest Monofilament detected - Ring finger, Dominant Hand									
'2.83		2 (8.0)				16 (20.3)			
'3.61		19 (76.0)				61 (77.2)			
'4.31		3 (12.0)				2 (2.5)			0.0360
'4.56		1 (4.0)				0 (0.0)			

Outcome	Age and Diabetes Adjusted Estimate		
	Estimate	95% CI	P-value
Eyedrop Installation			
Proportion of trials with no contamination	-0.13	-0.31, 0.05	0.1506
Proportion of trials with only 1 drop dispensed	0.05	-0.05, 0.16	0.3257
Average number of drops used to instill one over all trials	-0.17	-0.30, 0.08	0.2454
Proportion of trials with ≥ 1 drop in the eye	0.07	-0.01, 0.14	0.0747
Proportion of trials with ≥ 1 drop in the eye & no contamination	-0.11	-0.28, 0.07	0.2228
Proportion of trials with only 1 drop in the eye & no contamination	-0.07	-0.23, 0.09	0.4098
Sensorimotor Function			
Median Pinch Force - Dominant Hand (kg)	-0.9	-1.9, 0.1	0.0661
Median Grip Strength - Dominant Hand (kg)	-3.7	-8.9, 1.4	0.1527
Time to complete Grooved Pegboard - Dominant Hand (sec)	22.7	8.2, 37.3	0.0026
AHF Fasten/Unfasten 4 buttons (sec)	6.6	1.2, 12.1	0.0182
AHF Lacing shoe and tying bow (sec)	5.6	-0.7, 11.9	0.0787
AHF Pinning/Unpinning 2 safety pins (sec)	7.4	2.3, 12.6	0.0049
AHF Picking up/Manipulating 4 coins into a slot (sec)	1.2	-0.9, 3.4	0.2649
AHF Cutting putty into 4 pieces with knife (sec)	0.6	-1.1, 2.3	0.4931
AHF Sum all times (sec)	17.8	3.2, 32.4	0.0177
Median time to complete tactile testing (sec)	1.0	-0.1, 2.1	0.0760
Percent tactile accuracy	-8.5	-20.7, 3.7	0.1671

Journal Pre-proof



Journal Pre-proof



Despite reduced hand function, older adults with glaucoma achieved similar eye drop instillation success to those without glaucoma, but they had a higher incidence of bottle tip contact with the ocular surface, skin or eyelashes, suggesting an increased risk of potential contamination. Hand function deficits that occur as people age can pose challenges to eye drop instillation.

Journal Pre-proof